National Institute of Allergy and Infectious Diseases
Link to NIAID Home Page Link to NIAID Home Page Link to NIH Home Page
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

Respiratory Syncytial Virus
 Research
 Understanding
  Quick Facts
  Cause
  Transmission
  Symptoms
  Diagnosis
  Treatment
  Prevention


Respiratory Syncytial Virus

Quick Facts

  • Respiratory syncytial virus (RSV) typically causes cold-like symptoms such as a runny nose, cough, and congestion. Fevers are common. The infection can progress to the lower respiratory tract to cause more severe illness such as bronchiolitis (inflammation of the small airways in the lung) or pneumonia in otherwise healthy infants and young children.
  • RSV is highly contagious through close contact with infected people, and it can live on toys and other surfaces for several hours.
  • Most children will have an RSV infection by 2 years of age, and most will recover on their own within 8 to 15 days.
  • Every year, 75,000 to 125,000 children in the United States are admitted to the hospital for RSV infections.
  • For most children, fluids are the best treatment. Bronchodilators, medicines prescribed to help reduce airway resistance, may ease breathing in some cases. Antibiotics are ineffective against RSV but may be prescribed for complications that develop as a result of RSV.
  • Although deaths are relatively rare, RSV can be life-threatening for immune-compromised people, including premature infants, young children with heart and lung problems, and the elderly.
  • Researchers are working toward a vaccine, but none currently exist.  

back to top

 Volunteer for Clinial Studies Button ClinicalTrials.gov has a full list of NIAID-funded clinical studies related to RSV.

See Also

Mouse Model Suggests New Treatment Strategy for Severe RSV

E-mail Icon E-mail this page
Print Icon Print this page
 Volunteer for Clinial Studies Button ClinicalTrials.gov has a full list of NIAID-funded clinical studies related to RSV.

See Also

Mouse Model Suggests New Treatment Strategy for Severe RSV